Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response

HCV SVR, achievable now by means of DAA therapy, identifies a new class of patients requiring medical surveillance to be designed in relation to the liver disease stage advancement. To this end, identification of both disease biomarkers and therapeutic targets appears necessary.

Source: Journal of Hepatology - July 13, 2021 Category: Gastroenterology Authors: Claudia Montaldo, Michela Terri, Veronica Riccioni, Cecilia Battistelli, Veronica Bordoni, Gianpiero D ’Offizi, Maria Giulia Prado, Flavia Trionfetti, Tiziana Vescovo, Eleonora Tartaglia, Raffaele Strippoli, Chiara Agrati, Marco Tripodi Source Type: research